compound introduction
KY-226 是一种有效的、口服活性的 protein tyrosine phosphatase 1B (PTP1B) 的选择性变构抑制剂，对人PTP1B的IC50值为0.28 μM。KY-226 通过增强 insulin 和 leptin 信号传导来发挥抗糖尿病和抗肥胖的作用。IC50 为 0.25 μM，且不激活 PPARγ 。KY-226 还可以保护神经元免受脑缺血损伤。 Information KY-226 KY-226 is a potent, selective, orally active and allosteric inhibitor of protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.28 μM for human PTP1B activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. Targets PTP1B (Cell-free assay) 0.28 μM
